Benefits and Risks Associated With Aspirin Use in Patients With Diabetes for the Primary Prevention of Cardiovascular Events and Mortality: A Meta-Analysis

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2021 Sep 20

PMID 34539583

Citations 1

Authors

Hua Ma

Qing Gu

Huining Niu

Xiaohua Li

Rong Wang

Affiliations

Soon will be listed here.

Abstract

Purpose: A meta-analysis was conducted to assess the benefits and risks of aspirin for the primary prevention of cardiovascular disease and all-cause mortality events in adults with diabetes.

Methods: An extensive and systematic search was conducted in MEDLINE (via PubMed), Cinahl (via Ebsco), Scopus, and Web of Sciences from 1988 to December 2020. A detailed literature search was conducted using aspirin, cardiovascular disease (CVD), diabetes, and efficacy to identify trials of patients with diabetes who received aspirin for primary prevention of CVD. Demographic details with the primary outcome of events and bleeding outcomes were analyzed. The Cochrane Collaboration's risk of bias tool was used to assess the methodological quality of the included studies. Random-effects meta-analysis was used to calculate the pooled odds ratio for outcomes of cardiovascular events, death, and adverse events.

Findings: A total of 8 studies were included with 32,024 patients with diabetes; 16,001 allocated to aspirin, and 16,023 allocated to the control group. There was no difference between aspirin and control groups with respect to all-cause mortality, cardiovascular mortality, or bleeding events. However, MACE was significantly lower in the aspirin group.

Implications: Although aspirin has no significant risk on primary endpoints of cardiovascular events and bleeding outcomes in patients with diabetes compared to control, major adverse cardiovascular events (MACE) were significantly lower in the aspirin group. Further research on the use of aspirin alone or in combination with other antiplatelet drugs is required in patients with diabetes to supplement currently available research.

Systematic Review Registration: identifier [XU#/IRB/2020/1005].

Citing Articles

Factors Associated with Platelet Activation-Recent Pharmaceutical Approaches.

Theofilis P, Sagris M, Oikonomou E, Antonopoulos A, Tsioufis K, Tousoulis D Int J Mol Sci. 2022; 23(6).

PMID: 35328719 PMC: 8955963. DOI: 10.3390/ijms23063301.

References

Colwell J . Aspirin therapy in diabetes. Diabetes Care. 2002; 26 Suppl 1:S87-8. DOI: 10.2337/diacare.26.2007.s87. View

Pignone M, Alberts M, Colwell J, Cushman M, Inzucchi S, Mukherjee D . Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol. 2010; 55(25):2878-86. DOI: 10.1016/j.jacc.2010.04.003. View

Ittaman S, VanWormer J, Rezkalla S . The role of aspirin in the prevention of cardiovascular disease. Clin Med Res. 2014; 12(3-4):147-54. PMC: 4317158. DOI: 10.3121/cmr.2013.1197. View

Cosentino F, Grant P, Aboyans V, Bailey C, Ceriello A, Delgado V . 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 41(2):255-323. DOI: 10.1093/eurheartj/ehz486. View

. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice.... Lancet. 1998; 351(9098):233-41. View

Evangelista V, Totani L, Rotondo S, Lorenzet R, Tognoni G, De Berardis G . Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin. Thromb Haemost. 2005; 93(1):8-16. DOI: 10.1160/TH04-07-0453. View

Fox C, Coady S, Sorlie P, DAgostino Sr R, Pencina M, Vasan R . Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation. 2007; 115(12):1544-50. DOI: 10.1161/CIRCULATIONAHA.106.658948. View

Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R . The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008; 337:a1840. PMC: 2658865. DOI: 10.1136/bmj.a1840. View

Mahmoud A, Gad M, Elgendy A, Elgendy I, Bavry A . Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur Heart J. 2018; 40(7):607-617. DOI: 10.1093/eurheartj/ehy813. View

10.

Caldeira D, Alves M, David C, Costa J, Ferreira J, Pinto F . Aspirin in the primary prevention of cardiovascular disease on diabetic patients: Systematic review and meta-analysis. Prim Care Diabetes. 2019; 14(3):213-221. DOI: 10.1016/j.pcd.2019.11.004. View

11.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

12.

Tierney S, Fennessy F, Hayes D . ABC of arterial and vascular disease. Secondary prevention of peripheral vascular disease. BMJ. 2000; 320(7244):1262-5. PMC: 1117996. DOI: 10.1136/bmj.320.7244.1262. View

13.

Hansson L, Zanchetti A, Carruthers S, Dahlof B, Elmfeldt D, Julius S . Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998; 351(9118):1755-62. DOI: 10.1016/s0140-6736(98)04311-6. View

14.

Piepoli M, Hoes A, Agewall S, Albus C, Brotons C, Catapano A . 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by.... Eur Heart J. 2016; 37(29):2315-2381. PMC: 4986030. DOI: 10.1093/eurheartj/ehw106. View

15.

Hennekens C, DYKEN M, Fuster V . Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1997; 96(8):2751-3. DOI: 10.1161/01.cir.96.8.2751. View

16.

McNeil J, Nelson M, Woods R, Lockery J, Wolfe R, Reid C . Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. N Engl J Med. 2018; 379(16):1519-1528. PMC: 6433466. DOI: 10.1056/NEJMoa1803955. View

17.

Kunutsor S, Seidu S, Khunti K . Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. Diabet Med. 2016; 34(3):316-327. DOI: 10.1111/dme.13133. View

18.

Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J . Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med. 2018; 379(16):1529-1539. DOI: 10.1056/NEJMoa1804988. View

19.

Ajani U, Ford E, Greenland K, Giles W, Mokdad A . Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. Am J Prev Med. 2006; 30(1):74-7. DOI: 10.1016/j.amepre.2005.08.042. View

20.

Gelbenegger G, Postula M, Pecen L, Halvorsen S, Lesiak M, Schoergenhofer C . Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups. BMC Med. 2019; 17(1):198. PMC: 6827248. DOI: 10.1186/s12916-019-1428-0. View